Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

ZYDUS WORLDWIDE DMCC

Home Clinical Trial Sponsors and OrganizationsZYDUS WORLDWIDE DMCC

ZYDUS WORLDWIDE DMCC

ACTIVE

PO BOX 113536, Dubai, United Arab EmiratesSubsidiary

Part of Zydus Lifesciences Ltd.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

3

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Not Applicable

1

33.3%

Phase 3

1

33.3%

Trial Status Distribution

Completed

3

100.0%

Clinical Trials

Trials sponsored by this organization (3)

A clinical study of Sponsorâ€™s Vigabatrin 500 mg tablets compared to SABRILÂ® (Vigabatrin) Tablets 500mg to study the pharmacokinetics and safety in adult refractory complex partial-seizure patients.

May 202032 participants

Bioequivalence Study of Ivermectin Cream 1% in Treatment of Moderate to Severe Facial Rosacea

Oct 2019525 participants

A clinical study of Sponsorâ??s Vigabatrin 500 mg tablets compared to SABRILÂ® (Vigabatrin) Tablets 500mg to study the pharmacokinetics and safety in adult refractory complex partial-seizure patients.

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials3
Approvals
News

Back to Organizations